- Home
- SNSE vs PHIO Comparison
SNSE vs PHIO Comparison
Compare SNSE & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- PHIO
- Stock Information
- Founded
- SNSE 2005
- PHIO 2011
- Country
- SNSE United States
- PHIO United States
- Employees
- SNSE N/A
- PHIO N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- PHIO Health Care
- Exchange
- SNSE Nasdaq
- PHIO Nasdaq
- Market Cap
- SNSE 9.3M
- PHIO 8.6M
- IPO Year
- SNSE 2021
- PHIO N/A
- Fundamental
- Price
- SNSE $0.34
- PHIO $2.96
- Analyst Decision
- SNSE Strong Buy
- PHIO Strong Buy
- Analyst Count
- SNSE 4
- PHIO 2
- Target Price
- SNSE $4.25
- PHIO $9.00
- AVG Volume (30 Days)
- SNSE 150.3K
- PHIO 701.6K
- Earning Date
- SNSE 05-06-2025
- PHIO 05-15-2025
- Dividend Yield
- SNSE N/A
- PHIO N/A
- EPS Growth
- SNSE N/A
- PHIO N/A
- EPS
- SNSE N/A
- PHIO N/A
- Revenue
- SNSE N/A
- PHIO N/A
- Revenue This Year
- SNSE N/A
- PHIO N/A
- Revenue Next Year
- SNSE N/A
- PHIO N/A
- P/E Ratio
- SNSE N/A
- PHIO N/A
- Revenue Growth
- SNSE N/A
- PHIO N/A
- 52 Week Low
- SNSE $0.25
- PHIO $0.97
- 52 Week High
- SNSE $0.87
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- SNSE 50.22
- PHIO 77.11
- Support Level
- SNSE $0.31
- PHIO $1.71
- Resistance Level
- SNSE $0.33
- PHIO $2.08
- Average True Range (ATR)
- SNSE 0.04
- PHIO 0.18
- MACD
- SNSE 0.01
- PHIO 0.09
- Stochastic Oscillator
- SNSE 75.25
- PHIO 84.46
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.